LIMITED OFFER
Save 50% on book bundles
Immediately download your ebook while waiting for your print delivery. No promo code needed.
Curcumin-Based Nanomedicines as Cancer Therapeutics
- 1st Edition - February 21, 2024
- Editors: Amirhossein Sahebkar, Prashant Kesharwani
- Language: English
- Paperback ISBN:9 7 8 - 0 - 4 4 3 - 1 5 4 1 2 - 6
- eBook ISBN:9 7 8 - 0 - 4 4 3 - 1 5 4 1 3 - 3
Curcumin-based Nanomedicines as Cancer Therapeutics presents a consistent and thorough overview of nanocurcumin applications in cancer treatments. It brings together the novel ap… Read more
Purchase options
Institutional subscription on ScienceDirect
Request a sales quoteCurcumin-based Nanomedicines as Cancer Therapeutics presents a consistent and thorough overview of nanocurcumin applications in cancer treatments. It brings together the novel applications of nanocurcumin in biological milieu as well as helps readers to define the major gaps in knowledge that can lead to significant scientific discoveries.
Nanocurcumin has been widely explored for the treatment of various cancers; however, the scientific literature is inconsistent in style and structure and scattered across many sources. By providing an explicit account on vital aspects on nanocurcumin-based anticancer delivery approaches and discussing the perspectives of the technologies explored so far based upon the findings outlined, the book offers updated and in-depth knowledge on the topic in one single source written by global leading experts.
In addition, the book aims to stimulate the interest of the academic researchers, industrial scientists, businessmen, and young scholars to address key multidisciplinary challenges faced by nanotechnologists to foster the desired collaboration among biologists, chemists, physicists, engineers, and clinicians to find proper and efficient new cancer treatments.
Discusses the complete journey of curcumin delivery from fundamental to most recent anticancer applications using nanotechnology
Provides in-depth knowledge on novel anticancer application of nanocurcumin in biological milieu
Presents reliable and updated information for researchers on nanocurcumin-based anticancer targeted drug delivery
Graduate students and researchers in cancer research and nanotechnology, Graduate students and researchers in pharmaceutical related disciplines, medical doctors, oncologists
- Cover image
- Title page
- Table of Contents
- Copyright
- List of contributors
- Part A: Curcumin: Introduction, structure, andphysicochemical attributes
- 1. Curcumin: historical background, introduction, structure, and physicochemical attributes
- Abstract
- 1.1 Historical background
- 1.2 Characteristics
- 1.3 Components
- 1.4 Benefits, pharmacological effect, and potential therapeutic effect of turmeric and its major compound curcumin
- 1.5 Toxicity
- 1.6 Conclusion
- Conflict of interests
- References
- 2. Curcumin as a pharmaceutical leader
- Abstract
- 2.1 Introduction
- 2.2 Therapeutic activities of curcumin
- 2.3 Conclusion
- Conflict of interests
- References
- 3. Chemical structure and molecular targets of curcumin for cancer therapy
- Abstract
- 3.1 Introduction
- 3.2 Chemistry of curcumin
- 3.3 Functionalities and synthesis of natural curcumin
- 3.4 Curcumin revamped to super curcumin
- 3.5 Curcumin as tumor suppressor and its molecular targets
- 3.6 Curcumin for cancer therapy
- 3.7 Conclusion and future perspective
- Acknowledgment
- References
- 4. Structural features of curcumin and its effects on cancer-related signaling pathways
- Abstract
- 4.1 Curcumin chemistry
- 4.2 Changes in a structurally modified curcumin’s anticancer activity
- 4.3 Curcumin’s function on CDK inhibitors and CDK/cyclin complexes
- 4.4 P53 pathway and curcumin interaction
- 4.5 Curcumin’s targets in the cancer signaling pathway
- 4.6 Activation of Ras signaling by curcumin
- 4.7 Effect of curcumin in PI3K/AKT/mTOR signaling
- 4.8 Curcumin’s effect on Wnt/β-catenin signaling pathway
- 4.9 Role of curcumin on transcription factors in cancer
- 4.10 Role of curcumin in NF-κB and AP-1 signaling pathway
- 4.11 Role of curcumin in STAT signaling
- 4.12 Conclusions
- References
- 5. An overview of cellular, molecular, and biological aspect(s) of curcumin in cancer
- Abstract
- Abbreviation
- 5.1 Introduction
- 5.2 Inducing apoptosis
- 5.3 Tumor suppressor genes
- 5.4 The survival pathways
- 5.5 Angiogenesis
- 5.6 Metastasis
- 5.7 Conclusion
- References
- Part B: Smart drug delivery approaches for curcumindelivery in cancer therapy
- 6. Curcumin-drug conjugate-based drug delivery as cancer therapeutics
- Abstract
- 6.1 Introduction
- 6.2 Curcumin-drug conjugates in cancer therapy
- 6.3 Conclusion
- References
- 7. Curcumin microcapsule-based drug delivery as cancer therapeutics
- Abstract
- 7.1 Introduction
- 7.2 Microcapsule-based drug delivery systems
- 7.3 Methods for microencapsulation
- 7.4 Coating materials
- 7.5 Characterization of curcumin-loaded microcapsules
- 7.6 Coacervation
- 7.7 Other preparation techniques
- 7.8 Codelivery of curcumin using microcapsules
- 7.9 Antitumor efficiency of curcumin microcapsules
- 7.10 Conclusion
- References
- Part C: Recent advances and regulatory aspectsof gold nanoparticles
- 8. Nanoemulsion-based curcumin delivery systems as cancer therapeutics
- Abstract
- 8.1 Introduction
- 8.2 Nanoemulsions
- 8.3 Nanoemulsion structure
- 8.4 Preparation of nanoemulsions
- 8.5 Low-energy emulsification methods
- 8.6 High-energy emulsification methods
- 8.7 Physicochemical characteristics of nanoemulsions
- 8.8 Advantages of nanoemulsions as delivery systems
- 8.9 Nanoemulsions for delivery of curcumin
- 8.10 Parenteral curcumin nanoemulsions
- 8.11 Oral curcumin nanoemulsions
- 8.12 Curcumin nanoemulsions for cancer therapy
- 8.13 Passive targeting of curcumin nanoemulsions
- 8.14 Active targeting of curcumin nanoemulsions
- 8.15 Curcumin coloaded nanoemulsions for cancer therapy
- 8.16 Curcumin nanoemulsions in clinical trial
- 8.17 Conclusion
- References
- 9. Micelle-based curcumin delivery systems as cancer therapeutics
- Abstract
- 9.1 Introduction
- 9.2 Lipid-based micelles
- 9.3 Polymeric micelles
- 9.4 Future insights
- References
- 10. Liposome-based curcumin delivery systems as cancer therapeutics
- Abstract
- 10.1 Introduction
- 10.2 Conventional liposomes
- 10.3 Actively targeted liposome
- 10.4 Physical stimuli-responsive curcumin liposomal delivery systems
- 10.5 Microfluidic
- 10.6 Tissue engineering
- 10.7 Clinical studies
- 10.8 Future insights
- References
- 11. Inorganic nanoparticle-based curcumin delivery as cancer therapeutics
- Abstract
- 11.1 Introduction
- 11.2 Different types of inorganic nanoparticles
- 11.3 Conclusion
- References
- 12. PLGA nanoparticle-based curcumin delivery as cancer therapeutics
- Abstract
- 12.1 Introduction
- 12.2 Curcumin-PLGA nanoparticles in cancer therapy
- 12.3 Breast cancer
- 12.4 Ovarian cancer
- 12.5 Cervical cancer
- 12.6 Colorectal cancer
- 12.7 Prostate cancer
- 12.8 Liver cancer
- 12.9 Brain cancer
- 12.10 Other types of cancers
- 12.11 Combination therapy
- 12.12 Conclusion
- References
- 13. Polymersomes-based curcumin delivery as cancer therapeutics
- Abstract
- List of abbreviations
- 13.1 Introduction
- 13.2 Polymersomes as nanoformulations for curcumin delivery
- 13.3 Polymersomes for dual-drug delivery using responsiveness or surface functionalization
- 13.4 Final considerations
- Acknowledgments
- References
- Part D: Recent advances in nanocurcumin deliveryin cancer therapy
- 14. Biopolymer-based formulations for curcumin delivery toward cancer management
- Abstract
- 14.1 Introduction
- 14.2 Curcumin bioavailability
- 14.3 Curcumin’s absorption and stability
- 14.4 Utilizing nanotechnology to create derivatives of curcuma
- 14.5 Combination nanomedicine with curcumin
- 14.6 Different types of curcumin delivery systems used in cancer therapy
- 14.7 Biopolymer-based techniques for nanoencapsulation of curcumin
- 14.8 Anticarcinogenesis mechanisms of curcumin
- 14.9 Curcumin combination therapy’s drawbacks and future aspects
- References
- 15. Nanohybrid drug delivery approach as a novel opportunity for curcumin delivery in cancer
- Abstract
- 15.1 Introduction
- 15.2 Nanohybrids as promising tools for curcumin delivery
- 15.3 Conclusion
- References
- 16. Codelivery of curcumin and siRNA as anticancer therapeutics
- Abstract
- Graphical abstract
- 16.1 Introduction
- 16.2 Curcumin and its role in cancer prevention
- 16.3 Combination therapy of siRNA-curcumin
- 16.4 RNA-induced silencing complex
- 16.5 Targeting cancer with siRNA
- 16.6 Strategies of siRNA cancer therapy
- 16.7 Barriers to siRNA delivery
- 16.8 Nano drug delivery systems for codelivery of curcumin-siRNA
- 16.9 Conclusion
- References
- Part E: Challenges and future perspectives ofnano-curcumin drug delivery
- 17. Challenges associated with nanocurcumin anticancer drug delivery systems
- Abstract
- Abbreviations
- 17.1 Introduction
- 17.2 Curcumin
- 17.3 Types of anticancer nanocurcumin drug delivery systems
- 17.4 Photodynamic therapy
- 17.5 Combinatorial therapies
- 17.6 Clinical trials and patents
- 17.7 Addressing the research gap
- 17.8 Conclusion
- Declaration of interest
- References
- 18. Curcumin-loaded nanoparticles used for in vivo cancer models: an approach about their physicochemical properties and mechanism of action
- Abstract
- 18.1 Introduction
- 18.2 Curcumin
- 18.3 Nanoparticles
- 18.4 Cancer in vivo studies
- 18.5 Conclusion
- References
- 19. Clinical trials, patents, and marketed products of nanocurcumin-based anticancer drug delivery systems
- Abstract
- 19.1 Introduction
- 19.2 Results and discussion
- 19.3 Conclusions
- References
- Index
- No. of pages: 500
- Language: English
- Edition: 1
- Published: February 21, 2024
- Imprint: Academic Press
- Paperback ISBN: 9780443154126
- eBook ISBN: 9780443154133
AS
Amirhossein Sahebkar
Dr. Amirhossein Sahebkar received his PharmD and PhD (in Medical Biotechnology) degrees from the Mashhad University of Medical Sciences (MUMS; Mashhad, Iran). His research focuses on the investigation of novel natural products for the management of severe cardiometabolic disorders. He has conducted numerous research projects dealing with basic, experimental, and clinical research on curcuminoids.
Affiliations and expertise
Biotechnologist and Associate Professor of Medical Biotechnology, Mashhad University of Medical Sciences, IranPK
Prashant Kesharwani
Dr. Prashant Kesharwani is an assistant professor of pharmaceutics at School of Pharmaceutical Education and Research, Jamia Hamdard, New Delhi, India. He has more than 12 years of teaching, research, and industrial experience at international levels from various countries, including the United States, Malaysia, and India. An overarching goal of his current research is the development of nanoengineered drug delivery systems for various diseases. He has more than 300 international publications in well-reputed journals and more than 25 international books (Elsevier). He is a recipient of many research grants from various funding bodies. He is also the recipient of several internationally acclaimed awards, such as “USERN Laureate award”, most prestigious “Ramanujan Fellowship Award”. He actively participates in outreach and scientific dissemination for the service of the wider community.
Affiliations and expertise
Assistant Professor, Department of Pharmaceutics, School of Pharmaceutical Education and Research, Jamia Hamdard, New Delhi, IndiaRead Curcumin-Based Nanomedicines as Cancer Therapeutics on ScienceDirect